Lurasidone as a potential therapy for bipolar disorder.

Functional improvement was also observed in subscales of SDS; the SDS-social life subscore ( P = 0.003) and the SDS-family life/home responsibilities subscore (P = 0.003) were improved significantly when compared with the placebo group, and there was a nonsignificant trend towards improvement on the SDS-work/school subscore ( P = 0.068).

also in 5,406 other papers

More lurasidone patients with moderate to severe anxiety at baseline (52.0%) met anxiety treatment-responder criteria than patients with placebo (37.3%), but the difference did not reach statistical significance ( P = 0.102). 35 To date, there is no published clinical trial regarding the efficacy of lurasidone in the treatment of bipolar mania or maintenance.

also in 111,027 other papers